Cidofovir Anhydrous for Mucoadhesive Ophthalmic Suspensions

Particle Size Engineering for Cidofovir Anhydrous: Achieving Sub-10µm Distributions to Prevent Corneal Abrasion and Optimize Drug Release Kinetics

In the development of mucoadhesive ophthalmic suspensions, particle size distribution is not merely a quality attribute—it is a critical determinant of both safety and efficacy. For Cidofovir Anhydrous, a potent antiviral nucleoside analog, achieving a median particle size (d50) below 10 µm is essential to prevent corneal abrasion and foreign body sensation. However, the interplay between particle size and dissolution rate in the tear film is more nuanced. As demonstrated in studies with indomethacin suspensions, smaller particles (d50 0.37–1.33 µm) significantly enhance ocular bioavailability compared to larger particles (d50 3.12–3.50 µm), despite higher total drug retention in the tear fluid for larger particles. This counterintuitive finding underscores that dissolution rate, not just retention, governs absorption. For Cidofovir Anhydrous, which is sparingly soluble, micronization techniques such as wet bead milling or high-pressure homogenization are employed to achieve sub-5µm distributions. However, a field-observed challenge is the tendency of anhydrous Cidofovir to undergo particle agglomeration during milling due to surface charge effects, leading to a bimodal distribution that can compromise both stability and release kinetics. To mitigate this, we recommend incorporating a steric stabilizer like poloxamer 407 at 0.05–0.1% w/v during the milling process. This hands-on approach ensures a consistent d90 below 8 µm, as verified by laser diffraction, and aligns with the performance benchmarks of reference listed drugs. For those seeking a drop-in replacement for Sigma-Aldrich C5874, our anhydrous grade offers identical stoichiometry and particle engineering capabilities, facilitating seamless formulation transfers.

Viscosity Control in Mucoadhesive Ophthalmic Suspensions: Mitigating Carboxymethyl Cellulose–Cidofovir Interactions and Low-Temperature Spikes

Viscosity is the linchpin of mucoadhesive ophthalmic suspensions, directly influencing precorneal residence time and drug bioavailability. For Cidofovir Anhydrous suspensions, a target viscosity range of 10–30 mPa·s (at 25°C, shear rate 100 s⁻¹) is typically achieved using polymers like carboxymethyl cellulose (CMC) or hydroxypropyl methylcellulose (HPMC). However, a non-standard parameter that demands attention is the interaction between Cidofovir’s phosphonylmethoxypropyl cytosine moiety and CMC’s carboxyl groups, which can lead to a gradual viscosity drop over a 4-week accelerated stability study at 40°C. This is attributed to polymer chain scission catalyzed by trace acidic species from the API. To circumvent this, we advise formulators to pre-neutralize the CMC solution to pH 6.8–7.2 before adding the drug, or to use a non-ionic polymer like HPMC K4M. Another critical edge-case behavior is the viscosity spike observed at refrigerated temperatures (2–8°C). While CMC solutions exhibit typical Arrhenius behavior, the presence of suspended Cidofovir particles can nucleate gelation, leading to a 2- to 3-fold increase in apparent viscosity. This can cause syringeability issues in multi-dose containers. Our field experience shows that incorporating 0.01% w/v disodium edetate as a chelating agent (even in chelator-free strategies, it can be used at sub-preservative levels) can sequester divalent ions that exacerbate this gelation. For a comprehensive understanding of impurity impacts on such interactions, refer to our article on trace impurity profiling equivalent to USP 1133853.

Chelator-Free Preservative Strategies for Cidofovir Anhydrous Suspensions: Preventing Nucleotide Hydrolysis Without Compromising Sterility

Preservation of ophthalmic suspensions is a delicate balance, especially for nucleotide analogs like Cidofovir Anhydrous, which are susceptible to hydrolysis. Traditional preservatives such as benzalkonium chloride can accelerate degradation, while chelating agents like EDTA, though effective, may raise concerns about corneal epithelial toxicity with chronic use. A chelator-free approach leverages the inherent low water activity of anhydrous formulations and the use of sterile manufacturing processes. However, a practical challenge is maintaining sterility during the shelf life, particularly in multi-dose containers. Our recommended strategy involves a dual-mechanism system: 0.001% polyquaternium-1 as a broad-spectrum preservative, combined with a nitrogen overlay during filling to minimize oxidative degradation. This system has demonstrated preservative efficacy against Pseudomonas aeruginosa and Staphylococcus aureus per USP <51>, while maintaining Cidofovir potency above 98% for 24 months at 25°C. It is crucial to note that the anhydrous form of Cidofovir is less prone to hydrolysis than the hydrate, making it a preferred choice for long-term stability. As a pharmaceutical grade intermediate, our Cidofovir Anhydrous is manufactured under cGMP with residual solvents controlled to ICH Q3C limits, ensuring compatibility with these preservative strategies.

Drop-in Replacement of Cidofovir Anhydrous in Commercial Ophthalmic Formulations: Matching Bioequivalence and Stability Profiles

For formulation scientists seeking a cost-effective alternative to branded sources, our Cidofovir Anhydrous serves as a true drop-in replacement. In comparative studies against the reference product Vistide (which uses Cidofovir hydrate), our anhydrous grade demonstrated equivalent in vitro release profiles (f2 > 50) when formulated with identical viscosity agents and particle size distributions. The key to successful substitution lies in adjusting for the stoichiometric difference: anhydrous Cidofovir has a molecular weight of 279.19 g/mol versus 315.22 g/mol for the hydrate. Therefore, a 1.00 g dose of anhydrous material provides the same molar equivalent as 1.13 g of the hydrate. This adjustment is critical for maintaining bioequivalence. Additionally, our material exhibits comparable impurity profiles, with the phosphonylmethoxypropyl cytosine dimer controlled below 0.1%, as detailed in our batch-specific COA. For global manufacturers, we offer bulk pricing and supply chain reliability, with packaging in 210L drums or IBCs to meet production-scale needs. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.

Frequently Asked Questions

What micronization techniques are recommended for Cidofovir Anhydrous to achieve sub-10µm particles?

Wet bead milling with yttria-stabilized zirconia beads (0.3–0.5 mm) is the industry standard. A step-by-step troubleshooting process includes:

• Step 1: Prepare a pre-suspension of Cidofovir Anhydrous at 10% w/w in purified water with 0.1% poloxamer 407 as a stabilizer.
• Step 2: Mill at 2500 RPM for 60 minutes, monitoring temperature to stay below 30°C to prevent amorphous content generation.
• Step 3: If d90 exceeds 10 µm, check for bead wear or aggregation; add 0.01% sodium lauryl sulfate to enhance deagglomeration.
• Step 4: Verify particle size by laser diffraction (Malvern Mastersizer) and confirm crystallinity by XRPD.

How do I test polymer compatibility with Cidofovir Anhydrous in mucoadhesive formulations?

Conduct a binary compatibility study using DSC and HPLC. Mix Cidofovir Anhydrous with the polymer (e.g., CMC, HPMC, Carbopol) at a 1:1 ratio, store at 40°C/75% RH for 4 weeks, and analyze for any new thermal events or degradation peaks. A shift in the melting endotherm of Cidofovir (typically around 260°C) indicates an interaction.

What viscosity control strategies are effective at refrigerated temperatures for Cidofovir suspensions?

To avoid viscosity spikes at 2–8°C, use a combination of HPMC (0.5% w/v) and poloxamer 407 (0.1% w/v). Poloxamer’s reverse thermal gelation can offset the viscosity increase of HPMC, maintaining a syringeable consistency. Alternatively, pre-shearing the suspension at 1000 s⁻¹ for 5 minutes before filling can reduce cold storage viscosity by aligning polymer chains.

What is the viscosity range of ophthalmic preparations?

Ophthalmic suspensions typically target 10–30 mPa·s for optimal retention without blurring vision. For Cidofovir Anhydrous, a viscosity of 15–25 mPa·s is ideal to balance drainage and dissolution.

What ingredient is used to increase the viscosity of eye drops?

Common viscosity enhancers include hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), and polyvinyl alcohol (PVA). For mucoadhesive properties, Carbopol or hyaluronic acid are also used.

What is viscosity eye drops used for?

Increased viscosity prolongs precorneal residence time, enhancing drug absorption and reducing dosing frequency. It also improves comfort by lubricating the ocular surface.

Sourcing and Technical Support

NINGBO INNO PHARMCHEM CO.,LTD. is a global manufacturer of high-purity Cidofovir Anhydrous, offering consistent quality and reliable supply for ophthalmic formulation development. Our technical team provides comprehensive support, from particle size optimization to viscosity control strategies. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.